{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T12:51:32Z","timestamp":1782219092248,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T00:00:00Z","timestamp":1497916800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cancer Immunol Immunother"],"published-print":{"date-parts":[[2017,11]]},"DOI":"10.1007\/s00262-017-2033-8","type":"journal-article","created":{"date-parts":[[2017,6,20]],"date-time":"2017-06-20T02:51:08Z","timestamp":1497927068000},"page":"1399-1410","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":117,"title":["Autoimmune diabetes induced by PD-1 inhibitor\u2014retrospective analysis and pathogenesis: a case report and literature review"],"prefix":"10.1007","volume":"66","author":[{"given":"Marie-L\u00e9a","family":"Gauci","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pauline","family":"Laly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiphaine","family":"Vidal-Trecan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barouyr","family":"Baroudjian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J\u00e9r\u00e9my","family":"Gottlieb","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nika","family":"Madjlessi-Ezra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laetitia","family":"Da Meda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Madelaine-Chambrin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martine","family":"Bagot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicole","family":"Basset-Seguin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9cile","family":"Pages","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samia","family":"Mourah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Boudou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C\u00e9leste","family":"Lebb\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Fran\u00e7ois","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2017,6,20]]},"reference":[{"key":"2033_CR1","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1056\/NEJMoa1412082","volume":"372","author":"C Robert","year":"2015","unstructured":"Robert C, Long GV, Brady B et al (2015) Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med 372:320\u2013330. doi:\n                        10.1056\/NEJMoa1412082","journal-title":"N Engl J Med"},{"key":"2033_CR2","doi-asserted-by":"publisher","first-page":"11823","DOI":"10.1073\/pnas.0505497102","volume":"102","author":"J Wang","year":"2005","unstructured":"Wang J, Yoshida T, Nakaki F et al (2005) Establishment of NOD-Pdcd1\u2212\/\u2212 mice as an efficient animal model of type I diabetes. Proc Natl Acad Sci USA 102:11823\u201311828. doi:\n                        10.1073\/pnas.0505497102","journal-title":"Proc Natl Acad Sci USA"},{"key":"2033_CR3","doi-asserted-by":"publisher","first-page":"1966","DOI":"10.2337\/db09-1135","volume":"59","author":"T Rajasalu","year":"2010","unstructured":"Rajasalu T, Brosi H, Schuster C et al (2010) Deficiency in B7\u2013H1 (PD-L1)\/PD-1 coinhibition triggers pancreatic \u03b2-cell destruction by insulin-specific, murine CD8 T-cells. Diabetes 59:1966\u20131973. doi:\n                        10.2337\/db09-1135","journal-title":"Diabetes"},{"key":"2033_CR4","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.clim.2007.05.013","volume":"125","author":"I Guleria","year":"2007","unstructured":"Guleria I, Gubbels Bupp M, Dada S et al (2007) Mechanisms of PDL1-mediated regulation of autoimmune diabetes. Clin Immunol 125:16\u201325. doi:\n                        10.1016\/j.clim.2007.05.013","journal-title":"Clin Immunol"},{"key":"2033_CR5","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-016-1835-4","volume":"65","author":"E Hansen","year":"2016","unstructured":"Hansen E, Sahasrabudhe D, Sievert L (2016) A case report of insulin-dependent diabetes as immune-related toxicity of pembrolizumab: presentation, management and outcome. Cancer Immunol Immunother 65:765\u2013767. doi:\n                        10.1007\/s00262-016-1835-4","journal-title":"Cancer Immunol Immunother"},{"key":"2033_CR6","doi-asserted-by":"publisher","first-page":"765","DOI":"10.1007\/s00262-015-1689-1","volume":"64","author":"J Martin-Liberal","year":"2015","unstructured":"Martin-Liberal J, Furness AJS, Joshi K et al (2015) Anti-programmed cell death-1 therapy and insulin-dependent diabetes: a case report. Cancer Immunol Immunother 64:765\u2013767. doi:\n                        10.1007\/s00262-015-1689-1","journal-title":"Cancer Immunol Immunother"},{"key":"2033_CR7","doi-asserted-by":"publisher","first-page":"e137","DOI":"10.2337\/dc15-0889","volume":"38","author":"M Mellati","year":"2015","unstructured":"Mellati M, Eaton KD, Brooks-Worrell BM et al (2015) Anti-PD-1 and anti-PDL-1 monoclonal antibodies causing type 1 diabetes. Diabetes Care 38:e137\u2013e138. doi:\n                        10.2337\/dc15-0889","journal-title":"Diabetes Care"},{"key":"2033_CR8","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.2337\/dc14-2349","volume":"38","author":"J Hughes","year":"2015","unstructured":"Hughes J, Vudattu N, Sznol M et al (2015) Precipitation of autoimmune diabetes with anti-PD-1 immunotherapy. Diabetes Care 38:e55\u2013e57. doi:\n                        10.2337\/dc14-2349","journal-title":"Diabetes Care"},{"key":"2033_CR9","doi-asserted-by":"publisher","first-page":"e182","DOI":"10.2337\/dc15-1331","volume":"38","author":"C Gaudy","year":"2015","unstructured":"Gaudy C, Cl\u00e9vy C, Monestier S et al (2015) Anti-PD1 pembrolizumab can induce exceptional fulminant type 1 diabetes. Diabetes Care 38:e182\u2013e183. doi:\n                        10.2337\/dc15-1331","journal-title":"Diabetes Care"},{"key":"2033_CR10","doi-asserted-by":"publisher","first-page":"383","DOI":"10.1007\/s12185-016-2101-4","volume":"105","author":"W Munakata","year":"2017","unstructured":"Munakata W, Ohashi K, Yamauchi N, Tobinai K (2017) Fulminant type I diabetes mellitus associated with nivolumab in a patient with relapsed classical Hodgkin lymphoma. Int J Hematol 105:383\u2013386. doi:\n                        10.1007\/s12185-016-2101-4","journal-title":"Int J Hematol"},{"key":"2033_CR11","doi-asserted-by":"publisher","first-page":"605","DOI":"10.1111\/1346-8138.13486","volume":"44","author":"Y Teramoto","year":"2017","unstructured":"Teramoto Y, Nakamura Y, Asami Y et al (2017) Case of type 1 diabetes associated with less-dose nivolumab therapy in a melanoma patient. J Dermatol 44:605\u2013606. doi:\n                        10.1111\/1346-8138.13486","journal-title":"J Dermatol"},{"key":"2033_CR12","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1620\/tjem.239.155","volume":"239","author":"Y Miyoshi","year":"2016","unstructured":"Miyoshi Y, Ogawa O, Oyama Y (2016) Nivolumab, an anti-programmed cell death-1 antibody, induces fulminant type 1 diabetes. Tohoku J Exp Med 239:155\u2013158. doi:\n                        10.1620\/tjem.239.155","journal-title":"Tohoku J Exp Med"},{"key":"2033_CR13","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1111\/jdi.12531","volume":"7","author":"M Okamoto","year":"2016","unstructured":"Okamoto M, Okamoto M, Gotoh K et al (2016) Fulminant type 1 diabetes mellitus with anti-programmed cell death-1 therapy. J Diabetes Investig 7:915\u2013918. doi:\n                        10.1111\/jdi.12531","journal-title":"J Diabetes Investig"},{"key":"2033_CR14","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1016\/j.ejca.2016.02.025","volume":"60","author":"L Hofmann","year":"2016","unstructured":"Hofmann L, Forschner A, Loquai C et al (2016) Cutaneous, gastrointestinal, hepatic, endocrine, and renal side-effects of anti-PD-1 therapy. Eur J Cancer 60:190\u2013199. doi:\n                        10.1016\/j.ejca.2016.02.025","journal-title":"Eur J Cancer"},{"key":"2033_CR15","doi-asserted-by":"publisher","first-page":"2016217454","DOI":"10.1136\/bcr-2016-217454","volume":"2016","author":"J Aleksova","year":"2016","unstructured":"Aleksova J, Lau PKH, Soldatos G, McArthur G (2016) Glucocorticoids did not reverse type 1 diabetes mellitus secondary to pembrolizumab in a patient with metastatic melanoma. BMJ Case Rep 2016:2016217454. doi:\n                        10.1136\/bcr-2016-217454","journal-title":"BMJ Case Rep"},{"key":"2033_CR16","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1186\/s40425-016-0196-z","volume":"4","author":"JR Lowe","year":"2016","unstructured":"Lowe JR, Perry DJ, Salama AKS et al (2016) Genetic risk analysis of a patient with fulminant autoimmune type 1 diabetes mellitus secondary to combination ipilimumab and nivolumab immunotherapy. J Immunother Cancer 4:89. doi:\n                        10.1186\/s40425-016-0196-z","journal-title":"J Immunother Cancer"},{"key":"2033_CR17","doi-asserted-by":"publisher","first-page":"e41","DOI":"10.1016\/j.jtho.2016.12.015","volume":"12","author":"Y Usui","year":"2017","unstructured":"Usui Y, Udagawa H, Matsumoto S et al (2017) Association of serum anti-GAD antibody and HLA haplotypes with type 1 diabetes mellitus triggered by nivolumab in patients with non-small cell lung cancer. J Thorac Oncol 12:e41\u2013e43. doi:\n                        10.1016\/j.jtho.2016.12.015","journal-title":"J Thorac Oncol"},{"key":"2033_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1007\/s00262-016-1913-7","volume":"66","author":"YK Chae","year":"2017","unstructured":"Chae YK, Chiec L, Mohindra N et al (2017) A case of pembrolizumab-induced type-1 diabetes mellitus and discussion of immune checkpoint inhibitor-induced type 1 diabetes. Cancer Immunol Immunother 66:25\u201332. doi:\n                        10.1007\/s00262-016-1913-7","journal-title":"Cancer Immunol Immunother"},{"key":"2033_CR19","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1684\/ejd.2016.2923","volume":"27","author":"K Ishikawa","year":"2017","unstructured":"Ishikawa K, Shono-Saito T, Yamate T et al (2017) A case of fulminant type 1 diabetes mellitus, with a precipitous decrease in pancreatic volume, induced by nivolumab for malignant melanoma: analysis of HLA and CTLA-4 polymorphisms. Eur J Dermatol 27:184\u2013185. doi:\n                        10.1684\/ejd.2016.2923","journal-title":"Eur J Dermatol"},{"key":"2033_CR20","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1056\/NEJM200002033420501","volume":"342","author":"A Imagawa","year":"2000","unstructured":"Imagawa A, Hanafusa T, Miyagawa JI et al (2000) A novel subtype of type 1 diabetes mellitus characterized by a rapid onset and an absence of diabetes-related antibodies. N Engl J Med 342:301\u2013307. doi:\n                        10.1056\/NEJM200002033420501","journal-title":"N Engl J Med"},{"key":"2033_CR21","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.diabet.2008.05.003","volume":"34","author":"C Moreau","year":"2008","unstructured":"Moreau C, Drui D, Arnault-Ouary G et al (2008) Fulminant type 1 diabetes in Caucasians: a report of three cases. Diabetes Metab 34:529\u2013532. doi:\n                        10.1016\/j.diabet.2008.05.003","journal-title":"Diabetes Metab"},{"key":"2033_CR22","doi-asserted-by":"publisher","first-page":"536","DOI":"10.1111\/jdi.12024","volume":"3","author":"A Imagawa","year":"2012","unstructured":"Imagawa A, Hanafusa T, Awata T et al (2012) Report of the committee of the Japan Diabetes Society on the research of fulminant and acute-onset type 1 diabetes mellitus: new diagnostic criteria of fulminant type 1 diabetes mellitus (2012). J Diabetes Investig 3:536\u2013539. doi:\n                        10.1111\/jdi.12024","journal-title":"J Diabetes Investig"},{"key":"2033_CR23","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1007\/s11892-016-0738-2","volume":"16","author":"V Lampasona","year":"2016","unstructured":"Lampasona V, Liberati D (2016) Islet autoantibodies. Curr Diab Rep 16:53. doi:\n                        10.1007\/s11892-016-0738-2","journal-title":"Curr Diab Rep"},{"key":"2033_CR24","doi-asserted-by":"publisher","first-page":"e89561","DOI":"10.1371\/journal.pone.0089561","volume":"9","author":"NM Kochupurakkal","year":"2014","unstructured":"Kochupurakkal NM, Kruger AJ, Tripathi S et al (2014) Blockade of the programmed death-1 (PD1) pathway undermines potent genetic protection from type 1 diabetes. PLoS ONE 9:e89561. doi:\n                        10.1371\/journal.pone.0089561","journal-title":"PLoS ONE"},{"key":"2033_CR25","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1111\/cei.12603","volume":"180","author":"R Fujisawa","year":"2015","unstructured":"Fujisawa R, Haseda F, Tsutsumi C et al (2015) Low programmed cell death-1 (PD-1) expression in peripheral CD4(+) T cells in Japanese patients with autoimmune type 1 diabetes. Clin Exp Immunol 180:452\u2013457. doi:\n                        10.1111\/cei.12603","journal-title":"Clin Exp Immunol"}],"container-title":["Cancer Immunology, Immunotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00262-017-2033-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00262-017-2033-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,10,17]],"date-time":"2017-10-17T08:29:07Z","timestamp":1508228947000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00262-017-2033-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,6,20]]},"references-count":25,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2017,11]]}},"alternative-id":["2033"],"URL":"https:\/\/doi.org\/10.1007\/s00262-017-2033-8","relation":{},"ISSN":["0340-7004","1432-0851"],"issn-type":[{"value":"0340-7004","type":"print"},{"value":"1432-0851","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,6,20]]}}}